Global Idiopathic Pulmonary Fibrosis (IPF) Market Report 2021: Market was Valued at $3271.3 Million in 2020 - Forecast to 2026
January 20, 2022 04:43 ET
|
Research and Markets
Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline...
Global Idiopathic Pulmonary Fibrosis Treatment Market Report 2020: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2014-2025
December 10, 2020 04:33 ET
|
Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added...
Global Ofev (Nintedanib) Drug Insight and Market 2020-2030: Overview, Regulatory Milestones, Market Competitors, Emerging Therapies
October 01, 2020 06:09 ET
|
Research and Markets
Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Ofev (Nintedanib) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Ofev (nintedanib) - Drug...
CPF Celebrates Historic Year of Progress in Pulmonary Fibrosis
December 30, 2014 14:05 ET
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) played an important role in much of the year's successes in Pulmonary Fibrosis (PF), helping to make...
CORRECTION - Two FDA Approvals on Same Day Renew Hope for Pulmonary Fibrosis Community
October 16, 2014 17:19 ET
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, CALIF., Oct. 16, 2014 (GLOBE NEWSWIRE) -- In its press release dated October 16, 2014 at 10:46 AM EST with the headline "Two FDA Approvals on Same Day Renew Hope for Pulmonary Fibrosis...
Two FDA Approvals on Same Day Renew Hope for Pulmonary Fibrosis Community
October 16, 2014 10:46 ET
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, CALIF., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Patients, families and researchers alike have anticipated for months the U.S. Food and Drug Administration (FDA) decisions on two drugs for...
CPF Applauds Two FDA Approvals Announced Today for First Drugs for Idiopathic Pulmonary Fibrosis
October 15, 2014 18:02 ET
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, CALIF., Oct. 15, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) applauds the two U.S. Food and Drug Administration (FDA) approvals announced today for Idiopathic...
Pulmonary Fibrosis Patients, Families Take Center Stage at FDA
September 29, 2014 15:25 ET
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Most FDA panels involve high-level executives and renowned medical professionals in their given areas of expertise. On Friday, however, patients...
FDA Chooses Four CPF Advocates to Speak on IPF Workshop Panel
September 25, 2014 12:45 ET
|
Coalition for Pulmonary Fibrosis (CPF)
DISTRICT OF COLUMBIA, Wash., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Four of the eight panelist to address the FDA tomorrow at the first U.S. Food and Drug Administration (FDA) workshop on Idiopathic...
September Most Important Month in History for U.S. Patients Suffering from Idiopathic Pulmonary Fibrosis: FDA Workshop, Impending Drug Decisions, PF Month Activities
September 11, 2014 16:14 ET
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Never before have there been so many opportunities for patients to be heard regarding a deadly lung disease than this month: the U.S. Food and...